Agency plans to release guidance early next week about who might benefit from choosing one booster over another
BNT162b2 Highly Effective Against Delta Variant in Teens
At seven to 21 days after second dose, estimated effectiveness was 90 percent against infection, 93 percent against symptomatic COVID-19
mRNA Vaccine More Effective Booster to ChAdOx1 nCoV-19
Heterologous ChAdOx1 nCoV-19/mRNA prime-boost vaccination more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19
Geriatrics-Focused Risk Factors ID’d for COVID-19 Death
Indicators other than age alone can be used to determine prognosis in older adults hospitalized with COVID-19
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 18 to 22, 2021. This …
BNT162b2 Effectively Prevents Pediatric COVID-19 Hospitalization
Two doses of Pfizer-BioNTech vaccine highly effective for preventing hospitalization among children aged 12 to 18 years
Michigan Data Show Routine Vaccinations Plummeted in Early Pandemic
Authors say catch-up vaccinations of doses missed throughout the pandemic needed to stem outbreaks of vaccine-preventable diseases
Pfizer Says Lower Dose of Its COVID-19 Vaccine Protects Younger Children
Dose used in trial that included more than 2,200 children was 10 mcg, while the adult dose is 30 mcg